Extended Data Fig. 3: Peak CAR T-cell levels by response. | Nature Cancer

Extended Data Fig. 3: Peak CAR T-cell levels by response.

From: Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial

Extended Data Fig. 3

Peak CAR T-cell levels normalized to baseline tumor burden (SPD) by (A) best overall response and (B) ongoing response. Associations of CAR T-cell levels with response were analyzed in the mITT population (N = 26). One patient with ongoing response was lost to follow-up at the time of data cutoff and was excluded (from panel B). CAR, chimeric antigen receptor; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; SPD, sum product of diameters.

Source data

Back to article page